[Clinical studies of methicillin resistant S. aureus (MRSA) infections during the recent 10 months in our department].

Recently MRSA occupies a prominent position in nosocomial infections. We experienced 9 cases of severe MRSA infections in our department during the 10 months from Apr. 1989 to Jan. 1990. We investigated the clinical background of them. THE RESULTS of studies were as followed: 1) All cases were inpatients. 2) All cases were considered to be compromised hosts. 3) In 7 cases many kinds of catheters and apparatuses were pre-indwelt . 4) In 8 cases over 2 kinds of antibiotics and in 7 cases 3rd generation cephems were pre-administered. 5) The 5 cases, who were selected for coagulase typing, all belonged to type II. 6) All cases had almost similar patterns of drug sensitivity and were resistant to large amounts of antibiotics. All cases had good sensitivity to minocycline. 7) THE RESULTS: 3 died of sepsis and respiratory failure and 6 were alive (MRSA strains were still isolated in 3 cases and were eradicated in the other 3 cases 1-4 months after the therapy was started).

[Clinical evaluation of cefmenoxime in chronic complicated urinary tract infection].

The efficacy of cefmenoxime (CMX), which is a third generation, beta-lactamase-resistant cephem with a broad antibacterial spectrum, was examined in 43 patients with chronic complicated urinary tract infections. The usual dosage regimen was given 2 approximately 4 g/day of CMX by intravenous drip infusion over 1 hour. The duration of treatment was 5 days. Fifteen patients were cured and 21 improved, and the effective rate was 83.7%. Bacterial eradication rate in these cases was 88.2%, especially eradication of the original pathogens such as Serratia marcescens, Proteus species and Klebsiella species, occurred in high frequency. Laboratory abnormalities were slight elevation of serum GOT and GPT in 2 cases. From these findings, CMX was considered to be very effective in complicated urinary tract infections.